发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment. 拼凑阿尔茨海默氏症的拼图：莱卡单抗在治疗中的作用。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-12-12 DOI: 10.2217/nmt-2023-0026
Danish Ali Ashraf, Hassan Tariq, Fathimath Shahaa Hassan, Farooq Kamran, Warda Mushtaq Khosa, Maha Mushtaq Khosa
{"title":"Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment.","authors":"Danish Ali Ashraf, Hassan Tariq, Fathimath Shahaa Hassan, Farooq Kamran, Warda Mushtaq Khosa, Maha Mushtaq Khosa","doi":"10.2217/nmt-2023-0026","DOIUrl":"https://doi.org/10.2217/nmt-2023-0026","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"257-259"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. 关于评估克拉利宾片对复发性多发性硬化症患者的长期疗效的简明摘要：CLASSIC-MS 研究。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-08-03 DOI: 10.2217/nmt-2023-0018
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi, Elisabetta Verdun di Cantogno
{"title":"A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.","authors":"Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi, Elisabetta Verdun di Cantogno","doi":"10.2217/nmt-2023-0018","DOIUrl":"10.2217/nmt-2023-0018","url":null,"abstract":"<p><strong>What is this summary about?: </strong>Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies.</p><p><strong>What were the results?: </strong>Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS.</p><p><strong>What do the results mean?: </strong>The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"261-268"},"PeriodicalIF":2.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients. 复发缓解型多发性硬化症患者使用预填充醋酸格拉默笔的满意度和实用性。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-11-01 DOI: 10.2217/nmt-2022-0031
Herbert Schreiber, Joachim Hipp, Fabian Roßnagel, Christiane Moritz
{"title":"Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.","authors":"Herbert Schreiber, Joachim Hipp, Fabian Roßnagel, Christiane Moritz","doi":"10.2217/nmt-2022-0031","DOIUrl":"10.2217/nmt-2022-0031","url":null,"abstract":"<p><p><b>Aim:</b> Evaluation of practicality and patient satisfaction of a glatiramer acetate (GA) prefilled pen in patients with relapsing-remitting multiple sclerosis (RRMS). <b>Patients & methods:</b> A cross-sectional, multicenter, observational study evaluating patients' experiences with the GA-pen 3 months after its first use by means of self-reporting questionnaires. Primary end point was the proportion of patients who were satisfied with the pen. <b>Results:</b> 80 patients participated in the study. The majority (83.7%) was satisfied with the pen and 95% rated its application as easy or very easy. <b>Conclusion:</b> Most patients were satisfied with the GA-pen and rated its application as easy or very easy. Among the 12 device features, starting the injection without an injection button was considered the most appreciated feature. Improvements in pen functionality and design might allow patients to overcome many difficulties with self-injection, even those leading to nonadherence. But, this hypothesis awaits further validation by real-world follow-up studies.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"281-288"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71425414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of diagnostic routines for suspected Alzheimer's disease patients in US-American and German primary care. 美国和德国基层医疗机构对疑似阿尔茨海默病患者的诊断程序比较。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-10-01 Epub Date: 2023-12-08 DOI: 10.2217/nmt-2023-0023
Felix Menne, Timo Grimmer, Carola G Schipke
{"title":"Comparison of diagnostic routines for suspected Alzheimer's disease patients in US-American and German primary care.","authors":"Felix Menne, Timo Grimmer, Carola G Schipke","doi":"10.2217/nmt-2023-0023","DOIUrl":"https://doi.org/10.2217/nmt-2023-0023","url":null,"abstract":"<p><p><b>Aim:</b> Thorough diagnostics are a prerequisite for the optimal treatment of Alzheimer's disease (AD). Biomarker-based diagnostics are standard in academia, data on practitioners' diagnostic workups is scarce. <b>Materials & methods:</b> Surveys in German and US healthcare providers (HCP) were conducted regarding diagnostics in presumed AD patients. A subsample of 153 German and 88 US professionals was analyzed in detail. <b>Results:</b> Fewer German physicians conduct AD diagnostics themselves compared with US colleagues (67% vs 99%; p < 0.0001). German doctors more often order diagnostics at other institutions (65% vs 45%; p < 0.005). No significant differences were found regarding the type of diagnostics ordered at other institutions. <b>Conclusion:</b> Diagnostic routines for suspected AD patients differ between German and US-American healthcare providers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"269-280"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. 醋酸格拉替默或IFN-β桥接疗法在计划妊娠的复发性多发性硬化症妇女中的应用
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2022-0032
Kerstin Hellwig, Sandra Thiel, Sabrina Haben, Andrea I Ciplea, Anna Kurzeja
{"title":"Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.","authors":"Kerstin Hellwig,&nbsp;Sandra Thiel,&nbsp;Sabrina Haben,&nbsp;Andrea I Ciplea,&nbsp;Anna Kurzeja","doi":"10.2217/nmt-2022-0032","DOIUrl":"https://doi.org/10.2217/nmt-2022-0032","url":null,"abstract":"<p><p><b>Aim:</b> To assess bridging glatiramer acetate (GA) or IFN-β for relapse prevention in women with relapsing multiple sclerosis planning pregnancy. <b>Materials & methods:</b> Participants discontinued disease-modifying therapies (DMTs) and received GA/IFN (early- or delayed-start) or no DMT (control) until pregnancy. <b>Results:</b> Annualized relapse rate was lower in delayed-start GA/IFN cohort versus control during washout/bridging. During washout/bridging, bridging with GA/IFN in this cohort reduced clinical activity, while disease activity increased in controls versus baseline. <b>Conclusion:</b> More data on GA/IFN bridging are needed. Women with low relapsing multiple sclerosis activity in the year prior to DMT discontinuation due to pregnancy planning benefited from GA/IFN bridging with lower annualized relapse rate versus no treatment and reduced clinical activity versus baseline during washout/bridging and pregnancy.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"223-234"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9796752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective. 帕金森氏病患者的电脑认知测试:印度视角
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0002
Moulika Mandal, Kashish Srivastava
{"title":"Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective.","authors":"Moulika Mandal,&nbsp;Kashish Srivastava","doi":"10.2217/nmt-2023-0002","DOIUrl":"https://doi.org/10.2217/nmt-2023-0002","url":null,"abstract":"<p><p><b>Aim:</b> This study investigates perspectives on computer-based assessments among elderly individuals with Parkinson's disease (PD) in India for more efficient usability of digital assessments for this population. <b>Materials & methods:</b> Content analysis was conducted on 30 participants diagnosed with PD, who were interviewed for their preferences and perspectives on integrating technology in healthcare assessments. <b>Results:</b> Elderly individuals with PD in India favored paper-pencil assessments over computer-based alternatives due to limited technological familiarity, resistance to change, lack of trust in healthcare technology and PD-related motor challenges. <b>Conclusion:</b> Elderly patients with Parkinson's in India indicated their discomfort with computer-based based cognitive assessment. Addressing barriers toward digital assessments in India is crucial for their successful implementation in healthcare.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"235-243"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10154383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease. 靶向代谢性谷氨酸受体治疗帕金森病。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0016
Philippe Huot
{"title":"Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease.","authors":"Philippe Huot","doi":"10.2217/nmt-2023-0016","DOIUrl":"https://doi.org/10.2217/nmt-2023-0016","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"203-206"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10173261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. 与其他口服治疗多发性硬化症的药物相比，克拉宾片的疗效总结：来自MSBase注册表的结果。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-08-01 Epub Date: 2023-06-07 DOI: 10.2217/nmt-2023-0005
Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven
{"title":"A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.","authors":"Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven","doi":"10.2217/nmt-2023-0005","DOIUrl":"10.2217/nmt-2023-0005","url":null,"abstract":"<p><strong>What is this summary about?: </strong>Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad<sup>®</sup>) compared with other oral treatments.</p><p><strong>What were the results?: </strong>Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.</p><p><strong>What do the results mean?: </strong>The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"215-221"},"PeriodicalIF":2.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9787063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study. 7天静修对帕金森病患者的影响:现象学研究。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0015
Lori M Bordenave, Corrine Fritcher Nelson, Becky G Farley, Tara L McIsaac
{"title":"Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study.","authors":"Lori M Bordenave,&nbsp;Corrine Fritcher Nelson,&nbsp;Becky G Farley,&nbsp;Tara L McIsaac","doi":"10.2217/nmt-2023-0015","DOIUrl":"https://doi.org/10.2217/nmt-2023-0015","url":null,"abstract":"<p><p><b>Aim:</b> Early and ongoing access to rehabilitation and exercise may preserve functional mobility and quality of life for persons with Parkinson disease (PwP). The aim of the current study was to describe the experience of PwP who participated in a 7-day retreat. <b>Materials & methods:</b> A phenomenological approach was used to describe the lived experience of PwP. <b>Results:</b> Three themes emerged from interviews: a community of shared information where participants discussed exercising and learning with other PwP; improved control of Parkinson's disease symptoms, including performing physical tasks more easily and renewed motivation for their long-term plans for exercise because of the retreat. <b>Conclusion:</b> A 7-day retreat for PwP positively impacted perceived control of disease-related symptoms and intentions to continue exercise.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"245-255"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9800530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis. 临床研究可以告诉我们evobrutinib（一种治疗多发性硬化症的潜在药物）的安全性。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-08-01 Epub Date: 2023-06-22 DOI: 10.2217/nmt-2023-0003
Xavier Montalban, Daniel Wallace, Mark C Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H Kao, Hans Guehring
{"title":"A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.","authors":"Xavier Montalban, Daniel Wallace, Mark C Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H Kao, Hans Guehring","doi":"10.2217/nmt-2023-0003","DOIUrl":"10.2217/nmt-2023-0003","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.</p><p><strong>What were the results?: </strong>Evobrutinib was well-tolerated by participants in all three studies. The number of side effects reported by participants taking the medication was very similar to those reported by participants taking the placebo (a 'dummy' treatment without a real drug). The most common side effects in clinical studies were urinary tract infections, headache, swelling of the nose and throat, diarrhoea and blood markers of potential liver damage (these returned to normal once the treatment was stopped).</p><p><strong>What do the results mean?: </strong>The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. <b>Clinical Trial Registration:</b> NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 4","pages":"207-213"},"PeriodicalIF":2.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9790150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信